Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions
Antibiotics · 04.08.2023 · 12 (8) · 1285
DOI: 10.3390/antibiotics12081285 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibiotics, online erschienen am 04.08.2023. Verfasst von Jozef Ficik und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Microbiology, Central Military Hospital, 034 26 Ružomberok, Slovakia. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Slovak Research and Development Agency, European Regional Development Fund; Operational Program Integrated Infrastructure, Cultural and educational grant agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic.
Abstract (Originalsprache)
The COVID-19 era brought about new medical challenges, which, together with nosocomial bacterial infections, resulted in an enormous burden for the healthcare system. One of the most alarming nosocomial threats was carbapenem-resistant Klebsiella pneumoniae (CRKP). Monitoring CRKP incidence and antimicrobial resistance globally and locally is vitally important. In a retrospective study, the incidence of CRKP in the pre-COVID-19 period (2017–2019) and the COVID-19 pandemic (2020–2022) was investigated in the Central Military Hospital in Ružomberok, Slovak Republic. The relative incidence of CRKP significantly increased during the COVID-19 period—by 4.8 times, from 0.18 to 0.76%. At the same time, 47% of CRKP-positive patients also had COVID-19. Twenty-six KPC and sixty-nine NDM-producing isolates were identified. CRKPs isolated in the year 2022 were submitted to whole genome sequencing, and their susceptibility was tested to cefiderocol, ceftazidime–avibactam, imipenem–relebactam and meropenem–vaborbactam, with excellent results. KPC-producing isolates were also highly susceptible to colistin (92%). The NDM isolates revealed lower susceptibility rates, including only 57% colistin susceptibility. ST-307 prevailed in KPC and ST-11 in NDM isolates. Despite the excellent activity of new antimicrobials, rational antibiotic policy must be thoroughly followed, supported by complementary treatments and strict anti-epidemic precautions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Clinical Microbiology, Central Military Hospital, 034 26 Ružomberok, Slovakia.
- Institute of Microbiology, Faculty of Medicine, Comenius University and the University Hospital in Bratislava, 811 08 Bratislava, Slovakia.
- Department of Molecular Biology, Faculty of Natural Sciences, Comenius University, 842 15 Bratislava, Slovakia.
- Comenius University Science Park, 841 02 Bratislava, Slovakia.
- Public Health Authority of the Slovak Republic, 826 45 Bratislava, Slovakia.
ORCID-Profile: Adriána Liptáková
Förderung
- Slovak Research and Development Agency
- European Regional Development Fund; Operational Program Integrated Infrastructure
- Cultural and educational grant agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic
- European Regional Development Fund
- Slovak Republic Ministry of Education
Zitieren
APA
Ficik, J., Andrezál, M., Drahovská, H., Böhmer, M., Szemes, T., Liptáková, A., & Slobodníková, L. (2023). Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions. Antibiotics, 12(8), 1285. https://doi.org/10.3390/antibiotics12081285
Vancouver
Ficik J, Andrezál M, Drahovská H, Böhmer M, Szemes T, Liptáková A, et al. Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions. Antibiotics. 2023;12(8):1285. doi:10.3390/antibiotics12081285
BibTeX
@article{Ficik2023,
author = {Ficik, Jozef and Andrezál, Michal and Drahovská, Hana and Böhmer, Miroslav and Szemes, Tomáš and Liptáková, Adriána and Slobodníková, Lívia},
title = {Carbapenem-Resistant Klebsiella pneumoniae in COVID-19 Era—Challenges and Solutions},
journal = {Antibiotics},
year = {2023},
volume = {12},
number = {8},
pages = {1285},
doi = {10.3390/antibiotics12081285}
}
EUVIMED